ZyVersa Therapeutics Inc (ZVSA)

[INV4]

ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

September 12 2023

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a paper in the peer-reviewed journal, Frontiers in Immunology, highlighting potential limitations of NLRP3 inhibition in attenuating CNS Inflammation associated with activation of multiple inflammasome pathways. This paper supports ZyVersa’s rationale for targeting inflammasome ASC with IC 100 to inhibit multiple inflammasome pathways, not just NLRP3, to control inflammation in various inflammatory diseases.

In the paper titled, “Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALS,” the authors conducted studies in various human cell lines and in an animal model of ALS. Data demonstrate that NLRP3 inhibition alone is insufficient to attenuate proinflammatory cytokine release and inflammatory cell death associated with activation of multiple inflammasome pathways. Likewise, NLRP3 inhibition alone did not ameliorate spinal cord inflammation in an ALS model.

The authors stated, “we hypothesize that strategies that impact multiple inflammasome pathways may hold more promise in CNS disorders like ALS where multiple inflammasomes are dysregulated.” To read the article Click Here.

“The research published in Frontiers in Immunology reinforces the need to inhibit more than the NLRP3 inflammasome pathway to control inflammation associated with activation of multiple inflammasomes,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “ZyVersa’s Inflammasome ASC inhibitor IC 100 is designed to inhibit formation of multiple types of inflammasomes to attenuate initiation of the inflammatory cascade, and to inhibit ASC specks to attenuate perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1ß early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1ß and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92019000/zyversa-therapeutics-announces-research-published

$ZVSA